Inovio Pharmaceuticals Valuation
| INO Stock | USD 1.63 0.02 1.24% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. Inovio Pharmaceuticals retains a regular Real Value of $3.11 per share. The prevalent price of the firm is $1.63. Our model calculates the value of Inovio Pharmaceuticals from evaluating the firm fundamentals such as Shares Outstanding of 68.7 M, return on equity of -3.28, and Return On Asset of -0.64 as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Inovio Pharmaceuticals' valuation include:
Price Book 4.5821 | Enterprise Value | Enterprise Value Ebitda (1.09) | Price Sales 614.1732 | Enterprise Value Revenue 382.9693 |
Undervalued
Today
Please note that Inovio Pharmaceuticals' price fluctuation is very risky at this time. Calculation of the real value of Inovio Pharmaceuticals is based on 3 months time horizon. Increasing Inovio Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Inovio Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Inovio Stock. However, Inovio Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.63 | Real 3.11 | Target 7.63 | Hype 1.57 | Naive 1.83 |
The intrinsic value of Inovio Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Inovio Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Inovio Pharmaceuticals helps investors to forecast how Inovio stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Inovio Pharmaceuticals more accurately as focusing exclusively on Inovio Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Inovio Pharmaceuticals' intrinsic value based on its ongoing forecasts of Inovio Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Inovio Pharmaceuticals' closest peers.
Inovio Pharmaceuticals Cash |
|
Inovio Pharmaceuticals Total Value Analysis
Inovio Pharmaceuticals is currently estimated to have company total value of 69.83 M with market capitalization of 111.99 M, debt of 11.87 M, and cash on hands of 348.13 M. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the Inovio Pharmaceuticals fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
69.83 M | 111.99 M | 11.87 M | 348.13 M |
Inovio Pharmaceuticals Investor Information
About 39.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 2.72. Inovio Pharmaceuticals had not issued any dividends in recent years. The entity had 1:12 split on the 25th of January 2024. Based on the key indicators related to Inovio Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Inovio Pharmaceuticals may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Inovio Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Inovio Pharmaceuticals has an asset utilization ratio of 0.19 percent. This suggests that the Company is making $0.001924 for each dollar of assets. An increasing asset utilization means that Inovio Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Inovio Pharmaceuticals Profitability Analysis
Based on Inovio Pharmaceuticals' profitability indicators, Inovio Pharmaceuticals may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Inovio Pharmaceuticals' ability to earn profits and add value for shareholders.Net Loss | First Reported 1998-12-31 | Previous Quarter -23.5 M | Current Value -45.5 M | Quarterly Volatility 23.8 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.65 | 0.84 |
|
|
For Inovio Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Inovio Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Inovio Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Inovio Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Inovio Pharmaceuticals over time as well as its relative position and ranking within its peers.
Inovio Pharmaceuticals Earnings per Share Projection vs Actual
By analyzing Inovio Pharmaceuticals' earnings estimates, investors can diagnose different trends across Inovio Pharmaceuticals' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Inovio Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Inovio Pharmaceuticals Ownership Allocation
Inovio Pharmaceuticals has a total of 68.7 Million outstanding shares. 30% of Inovio Pharmaceuticals outstanding shares are owned by outside corporations. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Inovio Pharmaceuticals Profitability Analysis
The company reported the last year's revenue of 217.76 K. Reported Net Loss for the year was (107.25 M) with loss before taxes, overhead, and interest of (56.65 M).About Inovio Pharmaceuticals Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Inovio Pharmaceuticals. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Inovio Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing Inovio Pharmaceuticals's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Inovio Pharmaceuticals's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Inovio Pharmaceuticals. We calculate exposure to Inovio Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Inovio Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -3.3 M | -3.2 M | |
| Pretax Profit Margin | (566.42) | (538.10) | |
| Operating Profit Margin | (593.59) | (563.91) | |
| Net Loss | (566.42) | (538.10) | |
| Gross Profit Margin | 0.84 | 0.65 |
Inovio Pharmaceuticals Current Valuation Indicators
Inovio Pharmaceuticals' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Inovio Pharmaceuticals' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Inovio Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Inovio Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Inovio Pharmaceuticals' worth.When determining whether Inovio Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Inovio Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inovio Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inovio Pharmaceuticals Stock: Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inovio Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Will Biotechnology sector continue expanding? Could Inovio diversify its offerings? Factors like these will boost the valuation of Inovio Pharmaceuticals. Market participants price Inovio higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Inovio Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (2.72) | Revenue Per Share | Quarterly Revenue Growth 0.14 | Return On Assets | Return On Equity |
Understanding Inovio Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Inovio's accounting equity. The concept of intrinsic value—what Inovio Pharmaceuticals' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Inovio Pharmaceuticals' price substantially above or below its fundamental value.
Please note, there is a significant difference between Inovio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Inovio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Inovio Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.